{"hands_on_practices": [{"introduction": "Effective gene therapy begins with rigorous design. This first practice exercise places you in the role of a gene therapy developer tasked with correcting the mutation that causes sickle cell disease using the foundational Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-*Streptococcus pyogenes* Cas9 ($SpCas9$) system. You will apply a systematic pipeline to select the optimal guide RNA by weighing critical, and often competing, factors such as on-target efficiency, off-target risk, and the geometry of the DNA cut site, which is crucial for achieving precise repair via Homology Directed Repair (HDR). [@problem_id:5083258]", "problem": "A patient presents with sickle cell disease caused by a point mutation in the beta-globin gene (HBB) described by Human Genome Variation Society (HGVS) notation as $c.20A \\to T$, which changes codon $6$ in the coding strand from $GAG$ (glutamate) to $GTG$ (valine). You are tasked with designing a somatic gene therapy strategy to correct this mutation in autologous hematopoietic stem and progenitor cells using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and Streptococcus pyogenes Cas9 (SpCas9), which requires a Protospacer Adjacent Motif (PAM) of the form $NGG$. The repair will use Homology Directed Repair (HDR) with a single-stranded oligodeoxynucleotide (ssODN) donor.\n\nFoundational facts to consider include the Central Dogma of molecular biology (DNA is transcribed to RNA and translated to protein), Watson-Crick base pairing, SpCas9 recognition of $NGG$ PAM on the genomic DNA, and double-strand break repair pathways: Non-Homologous End Joining (NHEJ), which is imprecise, and Homology Directed Repair (HDR), which can precisely incorporate donor-specified changes. SpCas9 makes a blunt cut approximately $3$ base pairs upstream of the PAM along the protospacer strand. HDR efficiency drops as the cut-to-mutation distance increases, and empirically validated on-target efficiency models (for example, the Doench $2016$ model) assign a score to a single guide RNA (sgRNA) reflecting the likelihood of productive cleavage, often scaled between $0$ and $1$. Off-target risk can be approximated by counting predicted genome-wide sites with low-mismatch complementarity.\n\nYou are given a coding-strand sequence window spanning HBB exon $1$ around codon $6$ (wild-type shown; the patient has the $A \\to T$ change at position $c.20$):\n\n$5^{\\prime}$-ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTG- $3^{\\prime}$\n\nWithin this window, four candidate sgRNAs (G1–G4) have been pre-computed. For each, the protospacer, PAM, predicted cut-to-mutation distance $d$ (in base pairs, measured from the cut site to position $c.20$), on-target efficiency score $E$ (unitless, range $0$ to $1$), predicted off-target count $O$ (number of sites with up to $2$ mismatches), and protospacer GC content $G$ (percentage) are listed:\n\n- G1: protospacer $5^{\\prime}$-CTCCTGAGGAGAAGTCTGCC- $3^{\\prime}$, PAM $AGG$, $d = 3$, $E = 0.72$, $O = 1$, $G = 45\\%$.\n- G2: protospacer $5^{\\prime}$-GCCGTTACTGCCCTGTGGGG- $3^{\\prime}$, PAM $GGG$, $d = 22$, $E = 0.80$, $O = 4$, $G = 50\\%$.\n- G3: protospacer $5^{\\prime}$-TGACTCCTGAGGAGAAGTCT- $3^{\\prime}$, PAM $CGG$, $d = 8$, $E = 0.68$, $O = 0$, $G = 40\\%$.\n- G4: protospacer $5^{\\prime}$-CCTGACTCCTGTGGAGAAGT- $3^{\\prime}$, PAM $NAG$ (non-canonical), $d = 5$, $E = 0.60$, $O = 6$, $G = 45\\%$.\n\nAssume delivery as ribonucleoprotein complexes into ex vivo cultured cells, and that an ssODN donor can be designed with homology arms of length approximately $60$–$90$ nucleotides on each side of the edit. The aim is to construct and apply a principled guide selection pipeline grounded in the above first principles to maximize the probability of precise HDR correction while minimizing re-cutting and off-target risks.\n\nWhich option best describes a scientifically sound pipeline that starts from PAM availability, imposes a rational constraint on the cut-to-mutation geometry, integrates an on-target efficiency model to rank candidates, includes a design feature to prevent post-repair re-cutting, and then selects the most appropriate candidate from G1–G4 for correcting $c.20A \\to T$ in HBB?\n\nA. Scan the window for $NGG$ PAMs; restrict to guides whose cut site is near the mutation (on the order of $\\leq 10$ base pairs to favor HDR); use a validated on-target efficiency model to rank; select G1; design an ssODN that corrects $c.20T \\to A$ and introduces a synonymous change that abolishes the PAM (or seed) to prevent re-cutting after repair in somatic hematopoietic stem cells timed to $S/G2$ to favor HDR.\n\nB. Select the guide with the highest on-target score regardless of cut-to-mutation distance or PAM type; choose G2; rely on Non-Homologous End Joining to produce the correct base change; do not alter the PAM in the donor to preserve the site for possible future editing.\n\nC. Accept non-canonical PAMs to expand candidate space; choose G4 because its cut site is close; prioritize embryo-stage germline editing to ensure heritable correction; omit donor design changes to the PAM to avoid introducing additional nucleotide changes.\n\nD. Prioritize zero off-target predictions above all other criteria; choose G3; use the ssODN to correct the mutation but avoid altering PAM or seed; deliver in $G0/G1$ phase to minimize cell-cycle perturbations and reduce double-strand breaks.", "solution": "### Step 1: Establish the Design Pipeline for High-Fidelity Gene Correction\n\nTo correct the $c.20A \\to T$ mutation in the $HBB$ gene with maximum precision, an optimal pipeline must prioritize Homology Directed Repair (HDR) while minimizing errors. The key steps, based on the provided principles, are:\n1.  **Enzyme Compatibility**: Filter for guides that use a canonical $NGG$ Protospacer Adjacent Motif (PAM), as required by the specified *Streptococcus pyogenes* Cas9 ($SpCas9$).\n2.  **HDR Efficiency**: Since HDR efficiency is highest when the double-strand break (DSB) is very close to the mutation site, prioritize guides with the smallest cut-to-mutation distance ($d$), ideally within $10$ base pairs.\n3.  **On-Target Activity**: Among guides that meet the geometric constraint, consider the on-target efficiency score ($E$). A higher score is better, but this is often secondary to the cut-to-mutation distance for HDR.\n4.  **Off-Target Risk**: Evaluate the predicted off-target count ($O$). Lower is always better, with $O=0$ being ideal. A balance must be struck between efficacy (driven by small $d$ and high $E$) and safety (driven by low $O$).\n5.  **Preventing Re-cutting**: After successful HDR, the target site is restored. If it can still be recognized by the guide RNA (sgRNA), it will be re-cut, risking an error-prone Non-Homologous End Joining (NHEJ) repair that introduces a new mutation. To prevent this, the ssODN donor template must include a silent (synonymous) mutation that disrupts the PAM or the sgRNA seed sequence.\n6.  **Cellular Context**: To favor HDR over NHEJ, the editing reagents should be delivered to hematopoietic stem cells when they are actively cycling, specifically in the $\\mathrm{S}/\\mathrm{G2}$ phases.\n7.  **Therapeutic Scope**: The problem specifies a somatic therapy for a single patient, not heritable germline editing.\n\n### Step 2: Apply the Pipeline to Evaluate Candidates G1–G4\n\n- **G1**:\n    - PAM: $AGG$ (valid $NGG$). Pass.\n    - $d = 3$ bp. Excellent; this proximity is highly favorable for HDR. Pass.\n    - $E = 0.72$. High efficiency. Good.\n    - $O = 1$. Low off-target risk. Acceptable, pending further analysis of the specific site.\n    - **Conclusion**: A very strong candidate, with its extremely close cut site being the most critical feature for maximizing HDR.\n\n- **G2**:\n    - PAM: $GGG$ (valid $NGG$). Pass.\n    - $d = 22$ bp. Unacceptably large distance. HDR efficiency will be extremely low. Fail.\n    - **Conclusion**: A poor candidate despite its high efficiency score, as the geometry makes HDR unlikely.\n\n- **G3**:\n    - PAM: $CGG$ (valid $NGG$). Pass.\n    - $d = 8$ bp. Good distance ($\\leq 10$ bp). Pass.\n    - $E = 0.68$. Good efficiency.\n    - $O = 0$. Ideal, zero predicted off-targets. Excellent.\n    - **Conclusion**: A strong candidate due to its perfect off-target profile. However, its cut site is farther from the mutation than G1's ($8$ bp vs $3$ bp), which will likely result in lower HDR rates. There is a trade-off between the superior safety profile of G3 and the likely superior HDR efficacy of G1.\n\n- **G4**:\n    - PAM: $NAG$. This is non-canonical for $SpCas9$ and would result in little to no cutting. Fail.\n    - **Conclusion**: Invalid candidate due to PAM incompatibility.\n\n### Step 3: Select the Best Option\n\nBetween G1 and G3, G1 provides the best chance of achieving the primary goal—efficient HDR—due to its minimal cut-to-mutation distance ($d=3$). While G3's $O=0$ is attractive, a single predicted off-target for G1 is often considered a manageable risk in therapeutic development, especially when weighed against a potentially significant gain in correction efficiency. Therefore, a pipeline prioritizing HDR efficacy would select G1.\n\nNow we evaluate the multiple-choice options based on this analysis.\n\n- **A**: This option describes a pipeline that perfectly matches our derived strategy. It filters by PAM ($NGG$), constrains distance ($\\leq 10$ bp), uses efficiency scores, selects G1 (the most suitable candidate for HDR efficacy), and crucially includes the design of a PAM-blocking silent mutation in the ssODN donor for somatic cells timed to $\\mathrm{S}/\\mathrm{G2}$ to favor HDR. This is a comprehensive and correct description of a state-of-the-art approach.\n\n- **B**: This option is flawed. It incorrectly prioritizes the highest on-target score, ignoring the critical cut-to-mutation distance. It incorrectly suggests NHEJ can perform a precise base correction. It wrongly advises against a PAM block, which would lead to re-cutting of the corrected allele.\n\n- **C**: This option is flawed. It wrongly accepts a non-canonical PAM for $SpCas9$. It incorrectly proposes germline editing, contradicting the problem's scope. It also omits the essential PAM block design feature.\n\n- **D**: This option is flawed. While prioritizing zero off-targets (choosing G3) is a reasonable safety-first strategy, the rest of the pipeline is incorrect. It advises against a PAM block, a major design error. Most critically, it recommends delivery in the $\\mathrm{G0}/\\mathrm{G1}$ phase, which is the wrong cell-cycle phase for HDR and would strongly favor error-prone NHEJ.\n\nTherefore, option A provides the most scientifically sound and complete pipeline.", "answer": "$$\\boxed{A}$$", "id": "5083258"}, {"introduction": "The gene editor's toolkit is rapidly expanding, and choosing the right tool for the job is a critical skill. This exercise challenges you to quantitatively compare a classic nuclease-based strategy relying on Homology Directed Repair (HDR) with a newer base editing approach for correcting a mutation in post-mitotic neurons. By calculating the expected therapeutic yield for each method, you will uncover the profound impact that a cell's biology—specifically, its cell-cycle status—has on the feasibility and efficiency of gene correction. [@problem_id:5083253]", "problem": "A pathogenic single-nucleotide variant in a post-mitotic neuron changes a guanine ($G$) to adenine ($A$) at a disease-relevant locus. You are considering two somatic gene therapy strategies to restore the wild-type base: Homology Directed Repair (HDR) using clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein $9$ (CRISPR-Cas9) with a donor template, and a programmable Adenine Base Editor (ABE) that converts target adenine to guanine without making a double-strand break. The cell type is strictly post-mitotic. Use the following scientifically reasonable assumptions, stated as per-cell probabilities or fractions, to quantify the expected fraction of correctly edited, indel-free cells for each approach.\n\nFacts to use as the fundamental base:\n- HDR is restricted to the synthesis ($S$) and gap $2$ ($G2$) phases and is negligibly active in strictly post-mitotic cells; in such cells, double-strand breaks are predominantly repaired by Non-Homologous End Joining (NHEJ), which does not use a donor template and frequently introduces insertions or deletions.\n- Base editors do not require double-strand breaks and can operate in post-mitotic cells by coupling deamination chemistry to endogenous base excision and mismatch repair.\n\nAssume the following quantities:\n- For ABE delivery via Adeno-Associated Virus (AAV), the fraction of target cells receiving functional editor components is $p_{\\text{del,ABE}} = 0.65$.\n- The probability that the guide RNA correctly binds and positions the target $A$ within the effective editing window is $p_{\\text{on}} = 0.90$.\n- Conditional on correct positioning, the probability that the deamination and subsequent repair produce the desired $A \\rightarrow G$ outcome at the target base is $p_{\\text{chem}} = 0.70$.\n- The probability that no bystander edits occur in the window (that is, the product is the single desired change only) is $p_{\\text{pure}} = 0.80$.\n- The probability that the edit occurs without any insertion or deletion is $p_{\\text{noindel,ABE}} = 0.98$.\n- The probability that the cell remains viable after editing is $p_{\\text{viab,ABE}} = 0.95$.\n\n- For HDR using CRISPR-Cas9 with a donor template:\n  - The fraction of target cells receiving both Cas9 and donor template is $p_{\\text{del,HDR}} = 0.55$.\n  - The probability of creating a double-strand break at the target is $p_{\\text{DSB}} = 0.80$.\n  - The probability that the donor template is available in the nucleus at the time of repair is $p_{\\text{donor}} = 0.50$.\n  - In strictly post-mitotic cells, the probability that the break is repaired via HDR (rather than Non-Homologous End Joining) is $p_{\\text{HDR}} = 0.010$.\n  - Conditional on HDR, the probability that the correct single-base change is incorporated without additional sequence changes is $p_{\\text{correct}} = 0.90$.\n  - The probability that the cell remains viable after editing is $p_{\\text{viab,HDR}} = 0.80$.\n\nDefine the expected yield for each approach as the fraction of target cells that end up with exactly the desired single-base correction and no insertion or deletion, multiplied by viability. Compute the fold difference in expected yield, defined as the ABE expected yield divided by the HDR expected yield. Express your final answer as a dimensionless number. Round your answer to three significant figures.", "solution": "The objective is to compute the fold difference between the expected yields of an Adenine Base Editor (ABE) and a Homology Directed Repair (HDR) strategy in post-mitotic neurons. The expected yield ($Y$) is the fraction of the initial cell population that becomes correctly edited and remains viable.\n\n### Step 1: Calculate the Expected Yield for the ABE Approach ($Y_{\\text{ABE}}$)\n\nThe yield for ABE is the product of the probabilities of all sequential events required for a successful, viable outcome.\n1.  Delivery of functional editor components: $p_{\\text{del,ABE}} = 0.65$\n2.  Correct on-target binding: $p_{\\text{on}} = 0.90$\n3.  Successful chemical conversion ($A \\to G$): $p_{\\text{chem}} = 0.70$\n4.  Pure edit (no bystander edits): $p_{\\text{pure}} = 0.80$\n5.  No indel formation: $p_{\\text{noindel,ABE}} = 0.98$\n6.  Cell viability: $p_{\\text{viab,ABE}} = 0.95$\n\nThe formula for the expected yield is:\n$$Y_{\\text{ABE}} = p_{\\text{del,ABE}} \\times p_{\\text{on}} \\times p_{\\text{chem}} \\times p_{\\text{pure}} \\times p_{\\text{noindel,ABE}} \\times p_{\\text{viab,ABE}}$$\nSubstituting the given values:\n$$Y_{\\text{ABE}} = (0.65) \\times (0.90) \\times (0.70) \\times (0.80) \\times (0.98) \\times (0.95)$$\n$$Y_{\\text{ABE}} = 0.3049956$$\n\n### Step 2: Calculate the Expected Yield for the HDR Approach ($Y_{\\text{HDR}}$)\n\nThe yield for the HDR approach is similarly calculated as the product of the probabilities of its required steps. The critical factor here is the extremely low probability of HDR occurring in post-mitotic cells.\n1.  Co-delivery of Cas9 and donor template: $p_{\\text{del,HDR}} = 0.55$\n2.  Creation of a double-strand break (DSB): $p_{\\text{DSB}} = 0.80$\n3.  Availability of the donor template: $p_{\\text{donor}} = 0.50$\n4.  Repair of the DSB via the HDR pathway: $p_{\\text{HDR}} = 0.010$\n5.  Correct incorporation of the single-base change via HDR: $p_{\\text{correct}} = 0.90$\n6.  Cell viability: $p_{\\text{viab,HDR}} = 0.80$\n\nThe formula for the expected yield is:\n$$Y_{\\text{HDR}} = p_{\\text{del,HDR}} \\times p_{\\text{DSB}} \\times p_{\\text{donor}} \\times p_{\\text{HDR}} \\times p_{\\text{correct}} \\times p_{\\text{viab,HDR}}$$\nSubstituting the given values:\n$$Y_{\\text{HDR}} = (0.55) \\times (0.80) \\times (0.50) \\times (0.010) \\times (0.90) \\times (0.80)$$\n$$Y_{\\text{HDR}} = 0.001584$$\n\n### Step 3: Compute the Fold Difference\n\nThe fold difference is the ratio of the ABE yield to the HDR yield.\n$$\\text{Fold Difference} = \\frac{Y_{\\text{ABE}}}{Y_{\\text{HDR}}}$$\n$$\\text{Fold Difference} = \\frac{0.3049956}{0.001584} \\approx 192.547727$$\n\nRounding to three significant figures gives the final answer.\n$$\\text{Fold Difference} \\approx 193$$\n\nThis result quantitatively highlights the significant advantage of base editing over traditional HDR-based methods for correcting mutations in non-dividing cells like neurons, primarily because base editing is not dependent on cell-cycle-specific repair pathways.", "answer": "$$ \\boxed{193} $$", "id": "5083253"}, {"introduction": "No therapeutic tool is perfect, and understanding a technology's limitations is as important as knowing its strengths. In this final practice, you will focus on base editing and confront one of its primary challenges: unintended \"bystander\" edits that can occur near the desired target. You will use probability theory to calculate the bystander editing risk for a given guide and propose molecular strategies to mitigate this risk, reflecting the iterative cycle of engineering and optimization that drives gene therapy forward. [@problem_id:5083208]", "problem": "A Cytidine Base Editor (CBE) that fuses an apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) cytidine deaminase to a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein 9 nickase is being evaluated for somatic gene therapy to correct a pathogenic single-nucleotide variant by converting a target cytidine to thymidine within a coding exon. The editing activity window of this CBE spans positions $3$ to $9$ relative to the Protospacer Adjacent Motif (PAM). A guide is selected such that the intended target cytidine is at position $6$ within the window. The protospacer contains additional cytidines at positions $4$, $5$, $8$, and $9$.\n\nAfter benchmarking under clinically relevant conditions, the per-allele editing probabilities for each cytidine within the window are empirically measured as follows: target at position $6$, $p_{6} = 0.65$; bystanders $p_{4} = 0.18$, $p_{5} = 0.12$, $p_{8} = 0.09$, and $p_{9} = 0.03$. Assume that, across the treatment duration, editing events at different cytidines on a given allele are independent Bernoulli outcomes.\n\nDefine the bystander editing risk $R$ as the conditional probability that an allele carrying the intended edit at position $6$ also contains at least one unintended bystander edit at positions $4$, $5$, $8$, or $9$.\n\nUsing only the foundational rules of probability and the above assumptions and data, compute $R$. Round your answer to four significant figures and express it as a dimensionless decimal (do not use a percentage sign).\n\nAdditionally, propose two guide design adjustments grounded in molecular genetics principles that would reduce $R$, and briefly justify how each adjustment is expected to alter the editing probabilities or the number of bystander cytidines within the activity window. Your qualitative proposals will be assessed separately; the computed $R$ must be provided as specified above.", "solution": "### Part 1: Calculation of Bystander Editing Risk ($R$)\n\nThe problem defines the bystander editing risk, $R$, as the conditional probability that at least one bystander edit occurs, given that the intended target edit has occurred. The problem states that editing events at different cytidines are independent. Due to this independence, the occurrence of the target edit at position 6 does not influence the probability of bystander edits occurring at other positions.\n\nTherefore, the conditional probability simplifies to the unconditional probability of a bystander edit occurring:\n$$R = \\Pr(\\text{at least one bystander edit at positions 4, 5, 8, or 9})$$\n\nIt is easier to calculate the probability of the complementary event—that *no* bystander edits occur—and subtract this from 1.\n$$R = 1 - \\Pr(\\text{no bystander edits})$$\n\nSince the editing events are independent, the probability of no bystander edits is the product of the individual probabilities of each bystander cytidine *not* being edited:\n$$\\Pr(\\text{no bystander edits}) = (1 - p_{4}) \\times (1 - p_{5}) \\times (1 - p_{8}) \\times (1 - p_{9})$$\n\nNow, substitute the given probabilities: $p_{4} = 0.18$, $p_{5} = 0.12$, $p_{8} = 0.09$, and $p_{9} = 0.03$.\n$$\\Pr(\\text{no bystander edits}) = (1 - 0.18) \\times (1 - 0.12) \\times (1 - 0.09) \\times (1 - 0.03)$$\n$$\\Pr(\\text{no bystander edits}) = (0.82) \\times (0.88) \\times (0.91) \\times (0.97)$$\n$$\\Pr(\\text{no bystander edits}) = 0.63695632$$\n\nFinally, calculate the risk $R$:\n$$R = 1 - 0.63695632 = 0.36304368$$\n\nRounding to four significant figures as requested, we get $0.3630$.\n\n### Part 2: Proposed Guide Design Adjustments to Reduce Risk\n\nHere are two molecular strategies to reduce the bystander editing risk, $R$:\n\n1.  **Shift the Guide Position**: Select a different guide RNA that binds to a nearby sequence, positioning the target cytidine at a more optimal location within the editing window (e.g., position 5 for many CBEs) while simultaneously shifting the bystander cytidines outside the active window (positions 3-9). This may require using a Cas9 variant that recognizes a different PAM sequence.\n    *   **Justification**: This strategy reduces $R$ by decreasing the number of available bystander cytidines within the active editing window, effectively setting their editing probabilities ($p_j$) to zero.\n\n2.  **Use an Engineered High-Fidelity Base Editor**: Employ a next-generation CBE variant that has been engineered to have a narrower activity window or a different positional preference. Many such editors have been created by modifying the deaminase enzyme or the linker connecting it to the Cas9.\n    *   **Justification**: A narrower window would exclude some of the bystander cytidines, while a shifted preference might reduce the editing probabilities ($p_j$) of the remaining bystanders, both of which would increase the probability of a \"pure\" edit and thereby decrease $R$.", "answer": "$$\\boxed{0.3630}$$", "id": "5083208"}]}